Cancer/Tumor Profiling Market by (Technology (Immunoassay, NGS, PCR, In-Situ Hybridization, Microarray), Cancer Type (Breast, Lung, Colorectal, Prostate, Melanoma)), Biomarker Type (Genomic, Protein), Application, Region - Global Forecast to 2025
[302 Pages Report] The global cancer/tumor profiling market size is projected to reach USD 13.9 billion by 2025 from USD 8.3 billion in 2020, at a CAGR of 10.9% during the forecast period. The increasing incidence of cancer across the globe and the growing use of biomarkers in tumor profiling are the primary growth drivers for this market. In addition, the increase in cancer research and funding initiatives and technological advancements in profiling technologies are also propelling the growth of the cancer/tumor profiling market.
Also, the increasing demand for personalized medicine and the growing need for point-of-care diagnostics is expected to offer significant growth opportunities for market players during the forecast period. On the other hand, the high capital investment required for biomarker discovery and the technical issues with sample collection and storage are the key factors restraining market growth to a certain extent.
Impact of Covid-19 on the cancer/tumor profiling market in the forecast period (2020-2025)
The cancer/tumor profiling market is not expected to be significantly impacted by the COVID-19 pandemic in 2020-2021. Due to the COVID-19 outbreak, there has been a significant drop in cancer testing and diagnosis due to measures and resources implemented towards coronavirus. However, several patients affected with COVID-19 were people with malignancies, due to which cancer has been identified as a risk factor for COVID-19. Research in this area is further undertaken to understand the dynamics of the infection better, which is expected to propel the cancer research field further. On the other hand, we are estimating that the major share of tumor diagnostic and prognostic testing of cancer, along with personalized medicine, will grow at a stable pace in the next five years. There is a huge deferment of treatment schedule of surgeries, radiation therapy, and chemotherapy sessions. Hence, the cancer treatment of surgeries, radiation therapy, and chemotherapy sessions should come to the levels of 2019 by the first quarter of 2021.
Drivers, Restraints, Opportunities, and Challenges in the Cancer/Tumor Profiling Market (2020-2025)
Driver: Increasing incidence of cancer
Rise in cancer incidences is one of the major contributors to market growth in the overall cancer/tumor profiling market. The increasing burden of cancer can be attributed to several factors, including population growth and aging, as well as the changing prevalence of certain causes of cancer linked to social and economic development.
Restraint: Technical issues in sample collection and storage in the cancer/tumor profiling market
Sample collection is one of the key issues faced by service providers, followed by access to these samples. Stringent quality control of these samples is required, and they need to be stored under the right conditions to avoid any loss.
Opportunity: Increasing demand for personalized medicine
Personalized medicine, which has become a core area of research in the healthcare industry, has entered mainstream clinical practice and is changing the way many diseases are identified, classified, and treated. These advancements are particularly evident in the area of oncology.
Challenge: Poor regulatory and reimbursement scenario
Technological advancements have enhanced the development and use of tumor profiling technologies to identify the key attributes of a patients disease at an early stage and thus guide the selection of the therapy to benefit a particular patient. The acceptance of biomarker-based tests in clinical applications requires evidence of the biomarkers clinical validity and utility. This is important not just only to help physicians in the decision-making process but also to achieve regulatory approvals and reimbursements for tests. However, amassing the data necessary to show clinical validity and utility may be a time-consuming and expensive process, which is further complicated by the lack of standard regulations.
The immunoassays segment is expected to account for the largest share of the market, by technology, in 2019
Based on technology, the cancer/tumor profiling market has been segmented into immunoassays, in situ hybridization, next-generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, microarrays, and other technologies. The immunoassays segment accounted for the largest market share in 2019. These assays are used as a gold standard to conduct tumor profiling on a large scale as they help measure the presence and concentration of analytes in a sample. These tests are used for cancer diagnosis, prognosis, and treatment decisions. Moreover, the information gained by these tests in clinical settings helps shorten hospital stays and decrease the severity of illnesses by identifying and assessing the progression of the disease, leading to improved therapeutic choices.
The lung cancer segment is expected to grow at the highest CAGR during the forecast period
Based on cancer type, the cancer/tumor profiling market has been segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancers. In 2019, the breast cancer segment accounted for the largest share of the cancer/tumor profiling market, followed by lung cancer. The high prevalence of breast cancer across the globe is the major factor contributing to the large share of this segment. However, the lung cancer segment is expected to register the highest during the forecast period. The increasing incidence of lung cancer worldwide and the rising need for early diagnosis are supporting the growth of this segment.
The protein biomarker segment is expected to grow at the highest CAGR during the forecast period
Based on biomarker type, the cancer/tumor profiling market is segmented into genetic biomarkers, protein biomarkers, and other biomarkers. In 2019, the genetic biomarkers segment accounted for the largest share of the cancer/tumor profiling market. The large share of this segment can be attributed to the high adoption of these biomarkers during cancer diagnosis and prognosis and in the biomarker discovery process. On the other hand, the protein biomarkers segment is estimated to grow at the highest CAGR during the forecast period majorly due to the increasing adoption of proteomic methods for biomarker research to improve the drug development process. They also showcase the enormous potential for directing personalized cancer therapy and treatment monitoring.
Research to account for the largest share of the market, by application, in 2019
Based on applications, the cancer/tumor profiling market is segmented into research and clinical applications. The research applications segment accounted for the largest share of the cancer/tumor profiling market in 2019. The large share of this segment is attributed to the increasing focus on biomarker discovery for drug development along with the rapidly growing field of personalized medicine. Additionally, the growing funding for cancer research is propelling the growth of the market.
The APAC market is expected to grow at the highest CAGR during the forecast period
The cancer/tumor profiling market in the Asia Pacific is expected to witness the highest CAGR during the forecast period. Factors such as the high incidence of cancer, growing proteomics and genomics research and increasing research funding, increasing investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics are expected to drive the growth of this market during the forecast period.
Key Market Players
The prominent players in the Cancer/Tumor Profiling Market are Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US), NanoString Technologies, Inc. (US), Sysmex Corporation (Japan), Ribomed Biotechnologies, Inc. (US), Guardant Health, Inc. (US), Foundation Medicine (US) Roche Diagnostics (Switzerland), (US), GenScript Biotech Corporation (China), Tempus Labs (US), Boreal Genomics Inc (Canada), Perthera (US), Agendia (US), Omniseq(US), Histogene X (Belgium).
Illumina is a molecular diagnostics company engaged in the development, manufacturing, and marketing of integrated systems for the analysis of genetic variations and biological functions. The company offers a wide range of integrated sequencing and microarray systems, consumables, and analysis tools to accelerate and simplify genetic analysis. The company operates under two unitsProduct Revenue and Services & Other Revenue. The Product Revenue unit consists of consumables and instruments revenue, while the Services and Other Revenue unit consists of sequencing, genotyping, and instrument service contract revenue.
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
:
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market size available for years |
20182025 |
|
Base year considered |
2019 |
|
Forecast period |
20202025 |
|
Forecast units |
Value (USD) |
|
Segments covered |
Technology, Cancer Type, Biomarker Type, Application and Region |
|
Geographies covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa |
|
Companies covered |
Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US), NanoString Technologies, Inc. (US), Sysmex Corporation (Japan), Ribomed Biotechnologies, Inc. (US), Guardant Health, Inc. (US), Foundation Medicine (US) Roche Diagnostics (Switzerland), (US), GenScript Biotech Corporation (China), Tempus Labs (US), Boreal Genomics Inc (Canada), Perthera (US), Agendia (US), Omniseq(US), Histogene X (Belgium). |
The research report categorizes the market into the following segments and subsegments:
Cancer/Tumor Profiling Market, by Technology
- COVID Impact on the Market, By Technology
- Immunoassays
- Next-Generation Sequencing
- Polymerase Chain Reaction
- Mass Spectrometry
- In-Situ Hybridization
- Microarrays
- Others
Cancer/Tumor Profiling Market, by Cancer Type
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma Cancer
- Other Cancer
Cancer/Tumor Profiling Market by Biomarker Type
- Genomic Biomarker
- Protein Biomarker
Cancer/Tumor Profiling Market by Application
- COVID Impact on the Market
- Research
- Biomarker Discovery
- Personalized Medicine
- Clinical Application
- Diagnostics
- Prognostics
- Screening
- Treatment & Monitoring
Cancer/Tumor Profiling Market, by Region
- COVID Impact on the Market
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Recent Developments
- In 2020, Illuminas COVID response: Illumina partnered with IDbyDNA Partner to deliver NGS Infectious Disease solutions. The partnership aims to accelerate NGS adoption of clinical infectious disease testing. This partnership also aims to make next-generation software with powerful bioinformatics software that can turn data into actionable insights.
- In 2018, Illumina acquired Edico Genome, a leading provider of data analysis acceleration solutions for NGS, to accelerate genomic data analysis.
- In 2018, Illumina signed an agreement to acquire Pacific Biosciences to integrate Pacifics sequencing solutions into the company and expand its offering of integrated workflows.
- In 2017, Illumina opened its Solutions Center in the Genopole Campus in France as a customer-training center to support the development of skills for the expanding genomics industry in the country.
Frequently Asked Questions (FAQ):
Which are the top industry players in the global cancer/tumor profiling market?
The top market players in the global cancer/tumor profiling Market include llumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US), NanoString Technologies, Inc. (US), Sysmex Corporation (Japan), Ribomed Biotechnologies, Inc. (US), Guardant Health, Inc. (US), Foundation Medicine (US) Roche Holdings Inc. (Switzerland), (US), Genscript Biotech Corporation (China), Tempus Labs (US), Boreal Genomics Inc (Canada), Perthera (US), Agendia (US), Omniseq (US), Histogene X (Belgium).
What are the top trends in the global cancer/tumor profiling market?
Trends in the global cancer/tumor profiling market:
- Integration of Omics Data
- Advances in Liquid Biopsy Tests
Opportunities in the global cancer/tumor profiling market:
- Increasing demand for personalized medicine
Which global cancer/tumor profiling technologies have been included in this report?
This report the following main segments:
- Immunoassays
- In situ hybridization
- Next generation sequencing (NGS)
- Polymerase chain reaction (PCR)
- Mass spectrometry
- Microarrays
Which geographical region is dominating in the global cancer/tumor profiling market?
The global cancer/tumor profiling market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. In 2019, Asia Pacific region dominated the global cancer/tumor profiling market. This growth can be attributed to rapidly incidence of cancer, growing proteomics and genomics research, increasing research funding, rising investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics in several APAC countries, are supporting the growth of the cancer/tumor market in the Asia Pacific region.
Which is the leading global cancer/tumor profiling technology?
The Immunoassays segment commanded the largest market share in 2019. The high market share of immunoassays can be attributed to the wide adoption of these assays as the gold standard to measure the presence and concentration of analytes in a sample. These tests are used in the diagnosis and prognosis of cancer, and they aid in making appropriate treatment decisions. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
Secondary Research
This research study involved the use of widespread secondary sources; directories; databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers; annual reports; and companies house documents. Secondary research was used to identify and collect information for this extensive, technical, market-oriented, and commercial study of global cancer/tumor profiling market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, key developments related to market, and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and related key executives from various key companies and organizations operating in cancer/tumor profiling market. The primary sources from the demand side include industry experts such as surgeons, physicians and doctors, and life science researchers.
A breakdown of the primary respondents is provided below:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by technology, by cancer type, by biomarker type, application, and region).
Data Triangulation
After arriving at the market size, cancer/tumor profiling market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments & subsegments, the data triangulation and market breakdown procedures were employed, wherever applicable.
Objectives of the Study
- To define, describe, segment, and forecast cancer/tumor profiling market by product, indication, application, end user, and region
- To provide detailed information about the factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to overall cancer/tumor profiling market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of cancer/tumor profiling market in five main regions along with their respective key countries, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
- To profile key players in cancer/tumor profiling market and comprehensively analyze their core competencies and market shares
- To track and analyze competitive developments, such as acquisitions; new product launches; expansions; collaborations, agreements, and partnerships; and R&D activities of the leading players in cancer/tumor profiling market
- To benchmark players within cancer/tumor profiling market using the "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the companys specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (Up to 5)
Geographic Analysis
- A further breakdown of the Latin American cancer/tumor profiling market into Brazil, Mexico, and the Rest of Latin America
- A further breakdown of European cancer/tumor profiling market into Switzerland, Netherlands, and the Rest of Europe.
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Cancer/Tumor Profiling Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Cancer/Tumor Profiling Market